Eli Lilly And Co (NYSE:LLY) price target raised to $102.00 by Morgan Stanley

ME Staff
-
0

Analyst Ratings For Eli Lilly And Co (NYSE:LLY)

Today, Morgan Stanley raised its price target on Eli Lilly And Co (NYSE:LLY) to $102.00 per share.

There are 9 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Eli Lilly And Co (NYSE:LLY) is Hold with a consensus target price of $100.1333 per share, a potential 1.80% upside.

Some recent analyst ratings include

  • 7/31/2018-SunTrust Banks Reiterated Rating of Buy.
  • 7/25/2018-Berenberg Bank was Downgraded by analysts at Berenberg Bank from a “Buy ” rating to a ” Hold” rating. They now have a $99.00 price target on the stock.

Recent Insider Trading Activity For Eli Lilly And Co (NYSE:LLY)
Eli Lilly And Co (NYSE:LLY) has insider ownership of 0.11% and institutional ownership of 75.98%.

  • On 7/26/2018 Jackson P Tai, Director, bought 2,168 with an average share price of $95.22 per share and the total transaction amounting to $206,436.96.
  • On 7/24/2018 Lilly Endowment Inc, Major Shareholder, sold 185,000 with an average share price of $92.03 per share and the total transaction amounting to $17,025,550.00.
  • On 7/5/2018 Lilly Endowment Inc, Major Shareholder, sold 170,000 with an average share price of $86.62 per share and the total transaction amounting to $14,725,400.00.
  • On 6/15/2018 Lilly Endowment Inc, Major Shareholder, sold 180,000 with an average share price of $86.65 per share and the total transaction amounting to $15,597,000.00.
  • On 6/14/2018 Daniel Skovronsky, SVP, bought 10,000 with an average share price of $86.22 per share and the total transaction amounting to $862,200.00.
  • On 6/13/2018 Lilly Endowment Inc, Major Shareholder, sold 11,104 with an average share price of $86.27 per share and the total transaction amounting to $957,942.08.
  • On 6/11/2018 Lilly Endowment Inc, Major Shareholder, sold 51,198 with an average share price of $86.38 per share and the total transaction amounting to $4,422,483.24.

About Eli Lilly And Co (NYSE:LLY)
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics, as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Recent Trading Activity for Eli Lilly And Co (NYSE:LLY)
Shares of Eli Lilly And Co closed the previous trading session at 98,59 +0,57 0,58 % with 1334496 shares trading hands.